Cargando…

No evidence for PALB2 methylation in high-grade serous ovarian cancer

BACKGROUND: High-grade serous ovarian cancers are a distinct histological subtype of ovarian cancer often characterised by a dysfunctional BRCA/Fanconi anaemia (BRCA/FA) pathway, which is critical to the homologous recombination DNA repair machinery. An impaired BRCA/FA pathway sensitises tumours to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mikeska, Thomas, Alsop, Kathryn, Mitchell, Gillian, Bowtell, David DL, Dobrovic, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636006/ https://www.ncbi.nlm.nih.gov/pubmed/23587053 http://dx.doi.org/10.1186/1757-2215-6-26

Ejemplares similares

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer
por: Song, Honglin, et al.
Publicado: (2021)

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
por: Mignogna, Chiara, et al.
Publicado: (2016)

Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
por: Christie, Elizabeth L., et al.
Publicado: (2019)

Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer
por: Natanzon, Yanina, et al.
Publicado: (2018)

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
por: Baumbusch, Lars O., et al.
Publicado: (2013)

Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection
por: Kristensen, Lasse S., et al.
Publicado: (2008)

Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene
por: Candiloro, Ida LM, et al.
Publicado: (2008)

Evidence against PALB2 involvement in Icelandic breast cancer susceptibility
por: Gunnarsson, Haukur, et al.
Publicado: (2008)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

A germline PALB2 pathogenic variant identified in a pediatric high-grade glioma
por: Zhong, Yiming, et al.
Publicado: (2020)

A serous borderline ovarian tumour in a transgender male adolescent
por: Millington, Kate, et al.
Publicado: (2020)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Assessing alternative base substitutions at primer CpG sites to optimise unbiased PCR amplification of methylated sequences
por: Candiloro, Ida L. M., et al.
Publicado: (2017)

Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
por: Kassuhn, Wanja, et al.
Publicado: (2021)

Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence
por: Tsonis, Orestis, et al.
Publicado: (2020)

Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer
por: Nath, Aritro, et al.
Publicado: (2021)

Validation of a primer optimisation matrix to improve the performance of reverse transcription – quantitative real-time PCR assays
por: Mikeska, Thomas, et al.
Publicado: (2009)

Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs
por: Eoh, Kyung Jin, et al.
Publicado: (2021)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
por: Reyes, Henry D., et al.
Publicado: (2019)

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
por: Ho, Gwo Yaw, et al.
Publicado: (2023)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

PALB2 mutations in German and Russian patients with bilateral breast cancer
por: Bogdanova, Natalia, et al.
Publicado: (2010)

Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c(+) Expression in Tumor
por: Magalhaes, Isabelle, et al.
Publicado: (2020)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023)

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2021)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Traumatic central serous chorioretinopathy
por: Steeples, Laura, et al.
Publicado: (2015)

Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer
por: Nodin, Björn, et al.
Publicado: (2012)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies
por: Yeo, Min-Kyung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c7frsqfdtemvt07gogp6rg46b6